Live CoolSculpting® Demonstration at ASDS 2013
October 03 2013 - 8:00AM
Business Wire
ZELTIQ® Aesthetics, Inc. (Nasdaq: ZLTQ), a medical
technology company focused on developing and commercializing
products utilizing its proprietary controlled-cooling technology
platform, today announced it is exhibiting at the American Society
for Dermatologic Surgery (ASDS) in Chicago, October 3-6, 2013.
CoolSculpting, developed by ZELTIQ, is a non-surgical, clinically
proven procedure designed to selectively reduce fat in treated
areas using a patented cooling technology. Live CoolSculpting
treatments will be performed in the ZELTIQ booth on Friday, October
4, 5:30 – 7 p.m. In addition, patient assessments will be
demonstrated on all three exhibit days. The assessments will focus
on Treatment to Transformation™, an advanced CoolSculpting concept
designed to promote global patient assessment to address all
potential treatment areas and then recommend the right number of
treatments to consistently achieve the desired results. In the
United States, CoolSculpting is cleared for non-invasive fat
reduction of the abdomen and flank.
WHAT:
CoolSculpting ZELTIQ Booth #704
WHEN:
ASDS Exhibit Hours Thursday, October 3, 2013, 12:30 p.m. – 7 p.m.
Friday, October 4, 2013, 9 a.m. – 1:30 p.m. and 3 p.m. – 7 p.m.
Saturday, October 5, 2013, 9 a.m. – 2 p.m.
WHERE:
American Society for Dermatologic Surgery (ASDS) Hyatt Regency
Chicago 151 East Wacker Drive Chicago, IL 60601
About ZELTIQ® Aesthetics, Inc.
ZELTIQ is a medical technology company focused on developing and
commercializing products utilizing its proprietary
controlled-cooling technology platform. ZELTIQ’s first commercial
product, the CoolSculpting System, is designed to selectively
reduce stubborn fat that may not respond to diet or exercise.
CoolSculpting is based on the scientific principle that fat cells
are more sensitive to cold than the overlying skin and surrounding
tissues. It utilizes patented technology of precisely controlled
cooling to reduce the temperature of fat cells in the treated area,
which is intended to cause fat cell elimination through a natural
biological process known as apoptosis. ZELTIQ developed
CoolSculpting to safely, noticeably and measurably reduce the fat
layer.
IC1463-AIn the United States CoolSculpting is cleared for
non-invasive fat reduction of the abdomen and flank.
ZELTIQ Aesthetics, Inc.Marlo Rodman,
925-918-1190mrodman@zeltiq.com
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jul 2023 to Jul 2024